Recent research on psychedelic-assisted psychotherapy has shown the great promise of this therapeutic approach for the treatment of numerous mental health conditions. Instead of medicating people away from their emotions, it promotes a reconnection with them. In the first clinical study of psilocybin-assisted therapy for treatment resistant depression, carried out by the Beckley/Imperial team, we found that, for the first time in the history of psychiatry, the mystical experience lies at the very heart of treatment efficacy:
Patients who demonstrated the greatest improvement in their depression scores (blue line – 9 responders) were those who had undergone a greater mystical experience during the psychedelic intervention. Lower ‘peak’ experience were reported in those with weaker therapeutic response (10 ‘non-responders’).
Similarly, in a study of psilocybin-assisted therapy for smoking cessation carried out in collaboration between Johns Hopkins University and the Beckley Foundation, smoking cessation outcomes were significantly correlated with measures of mystical experience on session days, as well as retrospective ratings of the personal meaning and spiritual significance of psilocybin sessions.
Although spirituality has been related to increases in both resilience and positive emotions, the field of transpersonal psychology remains largely under-recognised.
Mindfulness-based therapy is the first successful attempt at reintegrating spiritual practices with psychiatry. However, it often suffers from the same limitation as many other imported contemplative practices, namely that it has lost its essential, meaningful, spiritual component in translation from the Eastern to the Western world.
The same appears to be happening with psychedelic-assisted therapy. Psychedelics were originally used as a sacrament, by the Mazatecs of Oaxaca or the indigenous tribes of the Peruvian Amazon, for instance, but this dimension has largely been lost in our modern revisiting of the medical use of these compounds. The therapies proposed to accompany this unique experience – despite being reminiscent of certain aspects of Eastern philosophies – lack the sense of sacredness, transcendence and divinity, that is inherent to the psychedelic experience.
Providing a spiritual framework might considerably improve the therapeutic outcome of psychedelic-assisted therapy, improving long-term wellbeing by increasing the likelihood of a deeply transformative mystical experience, and helping to integrate it into everyday life.
Now that the field of psychiatry is contemplating its own limitations and witnessing the great potential of psychedelic-assisted therapy, the time may be ripe for the reintegration of spirituality into healthcare, as a source of healing, resilience, and flourishing.
The Beckley Foundation is working on the development of a multidisciplinary research programme whose aim will be two-fold:
Psilocybin for Depression
Type of publication